

# Maria Luisa Caadas

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/7709391/maria-luisa-canadas-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

49  
papers

839  
citations

18  
h-index

27  
g-index

51  
ext. papers

1,139  
ext. citations

5.7  
avg, IF

4.19  
L-index

#	Paper	IF	Citations
49	Validation and functional characterization of GWAS-identified variants for chronic lymphocytic leukemia: a CRUCIAL study.. <i>Blood Cancer Journal</i> , <b>2022</b> , 12, 79	7	
48	The power of genetic diversity in genome-wide association studies of lipids. <i>Nature</i> , <b>2021</b> ,	50.4	24
47	Pharmacogenetic Predictors of Response to Interferon Beta Therapy in Multiple Sclerosis. <i>Molecular Neurobiology</i> , <b>2021</b> , 58, 4716-4726	6.2	0
46	Association of ABCB1 and VEGFA gene polymorphisms with breast cancer susceptibility and prognosis. <i>Pathology Research and Practice</i> , <b>2020</b> , 216, 152860	3.4	5
45	Genetic Strategies to Understand Human Diabetic Nephropathy: In Silico Strategies for Molecular Data-Association Studies. <i>Methods in Molecular Biology</i> , <b>2020</b> , 2067, 241-275	1.4	
44	Effect of DPYD, MTHFR, ABCB1, XRCC1, ERCC1 and GSTP1 on chemotherapy related toxicity in colorectal carcinoma. <i>Surgical Oncology</i> , <b>2020</b> , 35, 388-398	2.5	3
43	Genome-wide association meta-analysis for early age-related macular degeneration highlights novel loci and insights for advanced disease. <i>BMC Medical Genomics</i> , <b>2020</b> , 13, 120	3.7	19
42	The Challenges of Chromosome Y Analysis and the Implications for Chronic Kidney Disease. <i>Frontiers in Genetics</i> , <b>2019</b> , 10, 781	4.5	2
41	Genetic Susceptibility to Chronic Kidney Disease - Some More Pieces for the Heritability Puzzle. <i>Frontiers in Genetics</i> , <b>2019</b> , 10, 453	4.5	33
40	Impact of single nucleotide polymorphisms on the efficacy and toxicity of EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer patients. <i>Mutation Research - Reviews in Mutation Research</i> , <b>2019</b> , 781, 63-70	7	7
39	Genetic associations between genes in the renin-angiotensin-aldosterone system and renal disease: a systematic review and meta-analysis. <i>BMJ Open</i> , <b>2019</b> , 9, e026777	3	31
38	Information on Genetic Variants Does Not Increase Identification of Individuals at Risk of Esophageal Adenocarcinoma Compared to Clinical Risk Factors. <i>Gastroenterology</i> , <b>2019</b> , 156, 43-45	13.3	9
37	Effect of CYP4F2, VKORC1, and CYP2C9 in Influencing Coumarin Dose: A Single-Patient Data Meta-Analysis in More Than 15,000 Individuals. <i>Clinical Pharmacology and Therapeutics</i> , <b>2019</b> , 105, 1477-1491	6.1	12
36	Proteomic and metabolomic approaches in the search for biomarkers in chronic kidney disease. <i>Journal of Proteomics</i> , <b>2019</b> , 193, 93-122	3.9	18
35	Pharmacogenetics of platinum-based chemotherapy: impact of DNA repair and folate metabolism gene polymorphisms on prognosis of non-small cell lung cancer patients. <i>Pharmacogenomics Journal</i> , <b>2019</b> , 19, 164-177	3.5	19
34	Impact of DNA repair, folate and glutathione gene polymorphisms on risk of non small cell lung cancer. <i>Pathology Research and Practice</i> , <b>2018</b> , 214, 44-52	3.4	9
33	Influence of IL6R gene polymorphisms in the effectiveness to treatment with tocilizumab in rheumatoid arthritis. <i>Pharmacogenomics Journal</i> , <b>2018</b> , 18, 167-172	3.5	17

32	Pharmacogenetic biomarkers of response in Crohn's disease. <i>Pharmacogenomics Journal</i> , <b>2018</b> , 18, 1-13	3.5	8
31	Diabetes-Related Neurological Implications and Pharmacogenomics. <i>Current Pharmaceutical Design</i> , <b>2018</b> , 24, 1695-1710	3.3	19
30	Genomic approaches in the search for molecular biomarkers in chronic kidney disease. <i>Journal of Translational Medicine</i> , <b>2018</b> , 16, 292	8.5	17
29	Contribution of genetic factors to platinum-based chemotherapy sensitivity and prognosis of non-small cell lung cancer. <i>Mutation Research - Reviews in Mutation Research</i> , <b>2017</b> , 771, 32-58	7	24
28	ABCB1 gene polymorphisms and response to chemotherapy in breast cancer patients: A meta-analysis. <i>Surgical Oncology</i> , <b>2017</b> , 26, 473-482	2.5	11
27	Interleukins as new prognostic genetic biomarkers in non-small cell lung cancer. <i>Surgical Oncology</i> , <b>2017</b> , 26, 278-285	2.5	16
26	Cytokine single-nucleotide polymorphisms and risk of non-small-cell lung cancer. <i>Pharmacogenetics and Genomics</i> , <b>2017</b> , 27, 438-444	1.9	6
25	Genetic and clinical biomarkers of tocilizumab response in patients with rheumatoid arthritis. <i>Pharmacological Research</i> , <b>2016</b> , 111, 264-271	10.2	21
24	Liquid biopsy in early stage lung cancer. <i>Translational Lung Cancer Research</i> , <b>2016</b> , 5, 517-524	4.4	24
23	Relevance of BRAF and NRAS mutations in the primary tumor and metastases of papillary thyroid carcinomas. <i>Head and Neck</i> , <b>2016</b> , 38, 1772-1779	4.2	3
22	ABCB1 C3435T gene polymorphism as a potential biomarker of clinical outcomes in HER2-positive breast cancer patients. <i>Pharmacological Research</i> , <b>2016</b> , 108, 111-118	10.2	10
21	Gene polymorphisms as predictors of response to biological therapies in psoriasis patients. <i>Pharmacological Research</i> , <b>2016</b> , 113, 71-80	10.2	15
20	Pharmacogenetic predictors of toxicity to platinum based chemotherapy in non-small cell lung cancer patients. <i>Pharmacological Research</i> , <b>2016</b> , 111, 877-884	10.2	26
19	Molecular biomarkers in colorectal carcinoma. <i>Pharmacogenomics</i> , <b>2015</b> , 16, 1189-222	2.6	10
18	Extrapolation of acenocoumarol pharmacogenetic algorithms. <i>Vascular Pharmacology</i> , <b>2015</b> , 74, 151-157	5.9	5
17	MET: a new promising biomarker in non-small-cell lung carcinoma. <i>Pharmacogenomics</i> , <b>2015</b> , 16, 631-47	2.6	20
16	Non-HER2 signaling pathways activated in resistance to anti-HER2 therapy in breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2015</b> , 153, 493-505	4.4	21
15	MET/HGF targeted drugs as potential therapeutic strategies in non-small cell lung cancer. <i>Pharmacological Research</i> , <b>2015</b> , 102, 90-106	10.2	3

14	De novo resistance biomarkers to anti-HER2 therapies in HER2-positive breast cancer. <i>Pharmacogenomics</i> , <b>2015</b> , 16, 1411-26	2.6	5
13	PTEN and PI3K/AKT in non-small-cell lung cancer. <i>Pharmacogenomics</i> , <b>2015</b> , 16, 1843-62	2.6	140
12	Novel BRAF1599Ins Mutation Identified in a Follicular Variant of a Papillary Thyroid Carcinoma: A Molecular Modeling Approach. <i>Endocrine Practice</i> , <b>2014</b> , 20, e75-9	3.2	2
11	Pharmacogenetics role in the safety of acenocoumarol therapy. <i>Thrombosis and Haemostasis</i> , <b>2014</b> , 112, 522-36	7	20
10	Prediction of stable acenocoumarol dose by a pharmacogenetic algorithm. <i>Pharmacogenetics and Genomics</i> , <b>2014</b> , 24, 501-13	1.9	10
9	Could 18F-FDG-PET/CT avoid unnecessary thyroidectomies in patients with cytological diagnosis of follicular neoplasm?. <i>Langenbeck's Archives of Surgery</i> , <b>2013</b> , 398, 709-16	3.4	17
8	Pharmacogenetics and Pharmacogenomics of Chronic Kidney Disease Comorbidities and Kidney Transplantation <b>2013</b> , 801-817		1
7	Pharmacogenetics of Oral Anticoagulants <b>2013</b> , 435-467		
6	Pharmacogenomics and Gut Microbiota Biomarkers in Obesity <b>2013</b> , 575-601		
5	Pharmacogenetic polymorphisms contributing to toxicity induced by methotrexate in the southern Spanish population with rheumatoid arthritis. <i>OMICS A Journal of Integrative Biology</i> , <b>2012</b> , 16, 589-95	3.8	40
4	Pharmacogenetics of osteoporosis: towards novel theranostics for personalized medicine?. <i>OMICS A Journal of Integrative Biology</i> , <b>2012</b> , 16, 638-51	3.8	7
3	Reduction of false-negative papillary thyroid carcinomas by the routine analysis of BRAF(T1799A) mutation on fine-needle aspiration biopsy specimens: a prospective study of 814 thyroid FNAB patients. <i>Annals of Surgery</i> , <b>2012</b> , 255, 986-92	7.8	31
2	BRAF1799A mutation in the primary tumor as a marker of risk, recurrence, or persistence of papillary thyroid carcinoma. <i>Endocrinología Y Nutrición (English Edition)</i> , <b>2011</b> , 58, 175-184		6
1	Apoptosis and necrosis in human ejaculated spermatozoa. <i>Human Reproduction</i> , <b>2004</b> , 19, 607-10	5.7	84